Antimicrobial Resistance in Methicillin-resistant to Newer Antimicrobial Agents

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2019 Sep 19

PMID 31527033

Citations 44

Authors

Richard R Watkins

Marisa Holubar

Michael Z David

Affiliations

Soon will be listed here.

Abstract

Infections caused by methicillin-resistant (MRSA) result in significant morbidity and mortality for patients in both community and health care settings. This is primarily due to the difficulty in treating MRSA, which is often resistant to multiple classes of antibiotics. Understanding the mechanisms of antimicrobial resistance (AMR) in MRSA provides insight into the optimal use of antimicrobial agents in clinical practice and also underpins critical aspects of antimicrobial stewardship programs. In this review we delineate the mechanisms, prevalence, and clinical importance of resistance to antibiotics licensed in the past 20 years that target MRSA, as well as new drugs in the pipeline which are likely to be licensed soon. Current gaps in scientific knowledge about MRSA resistance mechanisms are discussed, and topics in the epidemiology of AMR in that require further investigation are highlighted.

Citing Articles

Discovery and biological evaluation of nitrofuranyl-pyrazolopyrimidine hybrid conjugates as potent antimicrobial agents targeting and methicillin-resistant .

Saini S, Reddy G, Gangwar A, Kour H, Nadre G, Pandian R RSC Med Chem. 2025; .

PMID: 39829972 PMC: 11740095. DOI: 10.1039/d4md00826j.

Cannabinoids as Antibacterial Agents: A Systematic and Critical Review of In Vitro Efficacy Against and .

Niyangoda D, Aung M, Qader M, Tesfaye W, Bushell M, Chiong F Antibiotics (Basel). 2024; 13(11).

PMID: 39596719 PMC: 11591022. DOI: 10.3390/antibiotics13111023.

Characterization of resistance and virulence factors in livestock-associated methicillin-resistant Staphylococcus aureus.

Beshiru A, Igbinosa I, Akinnibosun O, Ogofure A, Dunkwu-Okafor A, Uwhuba K Sci Rep. 2024; 14(1):13235.

PMID: 38853154 PMC: 11163002. DOI: 10.1038/s41598-024-63963-3.

Secondary analysis of whole genomes reveals diverse antimicrobial resistance profiles.

Nitz A, Johnson D, Lupiyaningdyah P, Meinzer M, Ramsey J, Robinson C MicroPubl Biol. 2024; 2024.

PMID: 38741934 PMC: 11089388. DOI: 10.17912/micropub.biology.000903.

Infectious Diseases Impact on Biomedical Devices and Materials.

Brigmon M, Brigmon R Biomed Mater Devices. 2024; :1-8.

PMID: 38625309 PMC: 9616421. DOI: 10.1007/s44174-022-00035-y.

References

Munch D, Engels I, Muller A, Reder-Christ K, Falkenstein-Paul H, Bierbaum G . Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Antimicrob Agents Chemother. 2014; 59(2):772-81. PMC: 4335874. DOI: 10.1128/AAC.02663-14. View

Musser J, Kapur V . Clonal analysis of methicillin-resistant Staphylococcus aureus strains from intercontinental sources: association of the mec gene with divergent phylogenetic lineages implies dissemination by horizontal transfer and recombination. J Clin Microbiol. 1992; 30(8):2058-63. PMC: 265442. DOI: 10.1128/jcm.30.8.2058-2063.1992. View

Silverman J, Oliver N, Andrew T, Li T . Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001; 45(6):1799-802. PMC: 90548. DOI: 10.1128/AAC.45.6.1799-1802.2001. View

Kanesaka I, Fujisaki S, Aiba Y, Watanabe S, Mikawa T, Kanayama Katsuse A . Characterization of compensatory mutations associated with restoration of daptomycin-susceptibility in daptomycin non-susceptible methicillin-resistant Staphylococcus aureus and the role mprF mutations. J Infect Chemother. 2018; 25(1):1-5. DOI: 10.1016/j.jiac.2018.09.009. View

Pillai S, Sakoulas G, Wennersten C, Eliopoulos G, Moellering Jr R, Ferraro M . Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype. J Infect Dis. 2002; 186(11):1603-7. DOI: 10.1086/345368. View

Prince W, Ivezic-Schoenfeld Z, Lell C, Tack K, Novak R, Obermayr F . Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2013; 57(5):2087-94. PMC: 3632892. DOI: 10.1128/AAC.02106-12. View

Zhanel G, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagace-Wiens P . New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs. 2010; 70(7):859-86. DOI: 10.2165/11534440-000000000-00000. View

Turco T, Melko G, Williams J . Vancomycin intermediate-resistant Staphylococcus aureus. Ann Pharmacother. 1998; 32(7-8):758-60. DOI: 10.1345/aph.18017. View

Zhang H, Xiao M, Kong F, OSullivan M, Mao L, Zhao H . A multicentre study of meticillin-resistant Staphylococcus aureus in acute bacterial skin and skin-structure infections in China: susceptibility to ceftaroline and molecular epidemiology. Int J Antimicrob Agents. 2015; 45(4):347-50. DOI: 10.1016/j.ijantimicag.2014.12.014. View

10.

Farrell D, Flamm R, Sader H, Jones R . Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). Int J Antimicrob Agents. 2013; 41(4):337-42. DOI: 10.1016/j.ijantimicag.2012.12.013. View

11.

Abbott I, Jenney A, Jeremiah C, Mirceta M, Kandiah J, Holt D . Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia. Antimicrob Agents Chemother. 2015; 59(12):7837-41. PMC: 4649159. DOI: 10.1128/AAC.02015-15. View

12.

Tarnberg M, Nilsson L, Dowzicky M . Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010-2014. Int J Infect Dis. 2016; 49:141-8. DOI: 10.1016/j.ijid.2016.06.016. View

13.

Hamilton S, Alexander J, Choo E, Basuino L, Da Costa T, Severin A . High-Level Resistance of Staphylococcus aureus to β-Lactam Antibiotics Mediated by Penicillin-Binding Protein 4 (PBP4). Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444179. DOI: 10.1128/AAC.02727-16. View

14.

Mendes R, Smith T, Deshpande L, Diekema D, Sader H, Jones R . Plasmid-borne vga(A)-encoding gene in methicillin-resistant Staphylococcus aureus ST398 recovered from swine and a swine farmer in the United States. Diagn Microbiol Infect Dis. 2011; 71(2):177-80. DOI: 10.1016/j.diagmicrobio.2011.06.009. View

15.

Pfaller M, Flamm R, McCurdy S, Pillar C, Shortridge D, Jones R . Delafloxacin Broth Microdilution and Disk Diffusion Antimicrobial Susceptibility Testing Guidelines: Susceptibility Breakpoint Criteria and Quality Control Ranges for an Expanded-Spectrum Anionic Fluoroquinolone. J Clin Microbiol. 2018; 56(8). PMC: 6062791. DOI: 10.1128/JCM.00339-18. View

16.

Vakulenko S, Mobashery S . Versatility of aminoglycosides and prospects for their future. Clin Microbiol Rev. 2003; 16(3):430-50. PMC: 164221. DOI: 10.1128/CMR.16.3.430-450.2003. View

17.

Pfaller M, Sader H, Rhomberg P, Flamm R . Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017; 61(4). PMC: 5365668. DOI: 10.1128/AAC.02609-16. View

18.

Sutcliffe J, OBrien W, Fyfe C, Grossman T . Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013; 57(11):5548-58. PMC: 3811277. DOI: 10.1128/AAC.01288-13. View

19.

Patel J, Gorwitz R, Jernigan J . Mupirocin resistance. Clin Infect Dis. 2009; 49(6):935-41. DOI: 10.1086/605495. View

20.

Roch M, Gagetti P, Davis J, Ceriana P, Errecalde L, Corso A . Daptomycin Resistance in Clinical MRSA Strains Is Associated with a High Biological Fitness Cost. Front Microbiol. 2017; 8:2303. PMC: 5723333. DOI: 10.3389/fmicb.2017.02303. View